Figure S6 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules

作者：Andreas Gollner, Dorothea Rudolph, Ulrike Weyer-Czernilofsky, Rosa Baumgartinger, Peter Jung, Harald Weinstabl, Jürgen Ramharter, Rolf Grempler, Jens Quant, Joerg Rinnenthal, Alejandro Pérez Pitarch, Bojana Golubovic, Daniel Gerlach, Gerd Bader, Kristiane Wetzel, S. R. Otto, Christian Mandl, Guido Boehmelt, Darryl B. McConnell, Norbert Kraut, Patrizia Sini · 年份：2026 · DOI：10.1158/1535-7163.32715148 · 研究领域：GDF15 and Related Biomarkers、TGF-β signaling in diseases、Metabolism, Diabetes, and Cancer

<p>Preliminary mean serum GDF15 absolute change from baseline (pg/mL) vs. planned time [h] after administration of 45 mg on Day 1 in Cycle 1 of a Q3W schedule in patients with cancer (<i>n</i> = 27).</p>